Kardiologie im Spreebogen

At Kardiologie im Spreebogen in Berlin, most studies focus on cardiovascular diseases, especially conditions linked to atherosclerotic cardiovascular disease, atrial fibrillation, and broader heart and vascular disease. The research is aimed at testing new treatments, reducing major cardiovascular events, and improving protection against stroke, heart attack, and other serious complications.

• Atrial fibrillation research is evaluating new options to prevent cardioembolic events and lower stroke risk.
• Atherosclerotic cardiovascular disease studies are assessing therapies designed to reduce major adverse cardiovascular events.
• Elevated lipoprotein(a) and related lipid disorders are being studied to better control inherited risk factors for heart disease.
• Heart failure projects are exploring treatments for people with obesity and preserved or mildly reduced heart function.
• Type 2 diabetes with hypertension and existing cardiovascular disease is also a key area of treatment research.

These trials aim to improve long-term cardiovascular outcomes by testing whether newer therapies can outperform standard care or placebo in people at elevated risk.

The site also conducts research in nutritional and metabolic diseases, with a strong emphasis on lipoprotein disorders, heterozygous familial hypercholesterolaemia, and type 2 diabetes. This work is centered on identifying better ways to lower harmful cholesterol-related risk and support prevention of cardiovascular complications.

• Elevated Lp(a) and inherited lipid conditions are being studied to see whether new therapies can meaningfully reduce risk.
• Heterozygous familial hypercholesterolaemia research is focused on improving control of very high cholesterol in people with genetic disease.
• Lipoprotein disorder trials are examining whether treatment can lower dangerous lipid levels more effectively.
• Type 2 diabetes studies are looking at cardiovascular benefit in people with multiple metabolic risk factors.

Overall, these studies are designed to test innovative approaches for managing metabolic risk and preventing downstream heart and vascular disease.

In the area of eye diseases, the research site is involved in studies on myopia progression in children. The main goal is to evaluate whether a new eye-drop treatment can slow the worsening of nearsightedness and support better long-term vision health.

• Myopia progression in children is being studied to determine whether treatment can help slow the rate of worsening vision.
• Research is focused on finding a practical option for early intervention in pediatric eye care.

This work adds a pediatric ophthalmology dimension to the site’s broader clinical research portfolio.